| 영문 | receptor | 한글 | 수용체 |
|---|---|---|---|
| 설명 | 세포질내 또는 세포표면에 존재하는 분자구조로서 특이물질과 선택적으로 결합하며 결합에 의해 특이한 생리적 작용을 나타낸다. 펩티드호르몬, 신경전달물질, 항원, 보체, 면역글로불린에 대한 세포표면 수용체와 스테로이드에 대한 세포질내 수용체가 있다. |
||
| 영문 | carcinoembryonic antigen | 한글 | 암배아항원 |
|---|---|---|---|
| 설명 | 원래 태아의 장조직에서 정상적으로 존재하는 물질로 태아기 이후에는 존재하지 않는 물질이다. 그러나 위, 간, 허파 등의 암이 있는 경우에 성인에서도 존재한다. 이를 이용해서 암의 치료효과 판정이나 재발여부의 조사에 이용한다. |
||
| 영문 | gene | 한글 | 유전자 |
|---|---|---|---|
| 설명 | 유전자는 길게 띠를 형성한 DNA분자의 일부분으로 한 가지 물질을 만드는데 필요한 모든 정보를 갖춘 기능적인 단위이다. 예를 들어 인슐린이라는 물질의 유전자라고 하면 사람의 세포내에 있는 긴 DNA 분자 중에서 인슐린이라는 물질을 만드는데 필요한 모든 정보를 가지고 있는 한 부분을 가리키는 말이다. 고전적인 생물학에서는 유전자가 표현형을 결정하거나 지정하는 염색체의 일부분이라고 정의되었지만, 오늘날에는 유전자에 대해서 분자적 정의가 제안되고 있으며 그 정의는 하나의 유전자는 하나의 효소를 결정 또는 암호화하는 유전물질의 일부분이라는 개념으로 이것이 이른바 1개의 유전자 1개 효소가설(one gene-one enzyme hypothesis)이다. 즉 1개의 유전자는 1개의 효소를 제작하는데 필요한 유전정보를 가진다는 것이다. 현재 이 가설이 받아들여지고 있다. |
||
| 영문 | gene therapy | 한글 | 유전자요법 |
|---|---|---|---|
| 설명 | 유전병을 치료할 목적으로, 정상적으로 기능하는 단일유전자 혹은 복수유전자를 어떤 기원에서 얻어내어 생세포에 도입하는 것. 유전물질은 유전자삽입 조작에 의해 수용세포에로 도입된다. 즉, 유전자를 끼워 넣은 새로운 세포를 사용하는 치료로서 1980년 미국의 학자가 지중해빈혈환자에게 강행하여 비판을 받았지만, 미국 국립보건연구소는 1990년 9월 아데노신 데아미나아제(adenosine deaminase, ADA) 결핍증 환자의 림프구에 ADA 유전자를 끼워 넣는 치료를 시작한 이래 현재는 암을 포함한 많은 질병들을 치료하는 목적으로 쓰인다. |
||
| 영문 | antigen | 한글 | 항원 |
|---|---|---|---|
| 설명 | 특이한 면역반응을 일으킬 수 있는 어떠한 물질. 여기에서 말하는 특이한 면역반응이란 비특이적인 면역반응과는 반대되는 의미로 그 물질에 대해서 특이하게 반응할 수 있는 항체나 그 물질에 대해서 특이하게 반응할 수 있는 세포를 만드는 것을 말한다. |
||
| rea | rearrangement |
|---|---|
| HLA | histocompatibility leukocyte antigen; histocompatibility locus antigen; homologous leukocyte antibod... |
| ER | efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re... |
| RAR | rapidly adapting receptor; rat insulin receptor; retinoic acid receptor; right arm reclining; right ... |
| TSA | technical surgical assistance; toluene sulfonic acid; total shoulder arthroplasty; total solute abso... |
| CCR | complex chromosomal rearrangement |
|---|---|
| VDR | Vitamin D receptor gene |
| AR | androgen receptor gene |
| HU-MARA | human androgen receptor gene |
| LDLR | low density lipoprotein receptor gene |
| gene rearrangement, beta-chain T-cell antigen receptor | Ordered rearrangement of T-cell variable gene regions coding for the beta-chain of antigen receptors. (12 Dec 1998) |
|---|
| gene rearrangement, alpha-chain T-cell antigen receptor | Ordered rearrangement of T-cell variable gene regions coding for the alpha-chain of antigen receptors. (12 Dec 1998) |
|---|---|
| gene rearrangement, delta-chain T-cell antigen receptor | Ordered rearrangement of T-cell variable gene regions coding for the delta-chain of antigen receptors. (12 Dec 1998) |
| gene rearrangement, gamma-chain T-cell antigen receptor | Ordered rearrangement of T-cell variable gene regions coding for the gamma-chain of antigen receptors. (12 Dec 1998) |
| gene rearrangement | A structural alteration of a chromosome that causes a change in the orderof its loci. (09 Oct 1997) |
| gene rearrangement, b-lymphocyte | Ordered rearrangement of b-lymphocyte variable gene regions coding for the immunoglobulin chains, thereby contributing to antibody diversity. It occurs during the differentiation of the immature b-lymphocyte. (12 Dec 1998) |
| gene rearrangement, b-lymphocyte, heavy chain | Ordered rearrangement of b-lymphocyte variable gene regions thereby contributing to antibody diversity. It occurs during the first stage of differentiation of the immature b-lymphocyte. (12 Dec 1998) |
| gene rearrangement, b-lymphocyte, light chain | Ordered rearrangement of b-lymphocyte variable gene regions coding for the kappa or lambda light chains, thereby contributing to antibody diversity. It occurs during the second stage of differentiation of the immature b-lymphocyte. (12 Dec 1998) |
| gene rearrangement, t-lymphocyte | Ordered rearrangement of T-cell variable gene regions coding for the antigen receptors. (12 Dec 1998) |
| receptor-CD3 complex, antigen, T-cell | Molecule composed of the non-covalent association of the T-cell antigen receptor (receptors, antigen, T-cell) with the CD3 complex (antigens, CD3). This association is required for the surface expression and function of both components. The molecule consists of up to seven chains: either the alpha/beta or gamma/delta chains of the T-cell receptor, and four or five chains in the CD3 complex. (12 Dec 1998) |
| rearrangement | A restructuring; e.g., in a molecule. Amadori rearrangement, a rearrangement that occurs in cross-linking reactions seen in collagen and in protein glycosylations; e.g., conversion of N-glycosides of aldoses to N-glycosides of the corresponding ketoses. (05 Mar 2000) |
| DNA rearrangement | <molecular biology> Wholesale movement of sequences from one position to another in DNA, such as occur somatically, for example in the generation of antibody diversity. (18 Nov 1997) |
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
| amino acid receptor | <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor. (18 Nov 1997) |
| AMPA receptor | <cell biology> Glutamate operated ion channel. See: excitatory amino acid receptor channels. (05 Feb 1998) |
| ANP receptor | <molecular biology> Family of 3 receptors for atrial natriuretic peptide. ANP A and ANP B have intracellular guanylate cyclase and protein kinase like domains. ANP C, shares the extracellular ligand binding and transmembrane domains, but lacks the functional intracellular domains and is not thought to be involved in signal transduction. (18 Nov 1997) |
Synonyms : Gene Rearrangement, beta-Chain T Cell Antigen Receptor, T Cell beta-Chain Gene Rearrangement, T Lymphocyte beta-Chain Gene Rearrangement, Gene Rearrangement, beta Chain T Cell Antigen Receptor, T Cell Antigen Receptor beta Chain Gene Rearrangement
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|